Research programme: colon cancer therapies - Biogen Idec/CaprionAlternative Names: Colon cancer therapies research programme - Biogen Idec/Caprion
Latest Information Update: 22 Jun 2007
At a glance
- Originator Biogen Idec; Caprion Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Colorectal cancer